A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

March 14, 2025

Study Completion Date

January 15, 2026

Conditions
NeoplasmsNeoplasm MetastasisNon-Small-Cell Lung Cancer
Interventions
DRUG

EMB-01

"In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks).~Participants may continue to receive study drug until discontinuation criteria are met."

Trial Locations (5)

44718

RECRUITING

Gabrail Cancer Center Research, Canton

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute, Detroit

200030

RECRUITING

Shanghai Chest Hosptial, Shanghai

510080

RECRUITING

Guangdong General Hospital, Guangzhou

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Shanghai EpimAb Biotherapeutics Co., Ltd.

INDUSTRY

NCT03797391 - A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter